The table below shows Royalty Pharma plc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$2.38B
$2.26B
$2.35B
$2.24B
$2.29B
$2.12B
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$452.00M
$2.00M
$52.00M
$177.11M
$200.08M
$26.29M
SG&A
$573.48M
RPRX annual revenue (10-K history)
Royalty Pharma plc reported annual revenue of $2.38B for fiscal year 2025. That is up 5.1% from $2.26B in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $1.79B (FY 2018) to $2.38B. Figures come from the company's audited annual reports as filed with the SEC.